French biotechnology company Abolis Biotechnologies has launched MINE (Microbial INtelligence Explorer), a new microbial-intelligence platform designed to help innovators, manufacturers and R&D teams turn complex microbial and multi-omics data into actionable insights for product development, process optimisation and scale-up.

 

The platform connects microbial and multi-omics data with experimental findings and industrial insight, giving teams a way to identify relevant biological mechanisms, prioritise experiments and focus development efforts on the most credible routes to industrialisation.

 

Microbial systems offer significant potential for industries looking to improve product performance, strengthen supply-chain resilience and develop more sustainable production methods. But generating biological data is only part of the challenge. 

 

For manufacturers and R&D teams, the bigger question is how to interpret that data — and determine which metabolic mechanisms, parameters and development pathways warrant further investigation.

 

MINE has been built with industrial users to address that gap. The platform combines genomic exploration, multi-omics analysis and experimental interpretation, enabling teams to examine how individual strains contribute to the production of molecules of interest, investigate interactions within complex microbial systems and identify potential levers for process optimisation.

 

By linking biological findings to technical and industrial constraints, MINE helps partners prioritise experiments, identify validation requirements and direct resources towards development routes with the strongest supporting evidence.

 

The foundations of MINE were laid through Microbiome Studio, an ML-enabled analytical platform developed from the Metapath project, an industrial programme supported by the French government. Originally created for Abolis’ own microbial-biotechnology programmes, Microbiome Studio was refined through industrial collaborations before evolving into MINE for external R&D and open-innovation teams.

 

The platform is also designed to make microbial intelligence more accessible to R&D and open-innovation teams without requiring every decision-maker to be an omics or bioinformatics specialist. Backed by Abolis’ multidisciplinary scientific expertise, MINE enables partners to interpret biological evidence in the context of product objectives and technical requirements.

 

The launch expands Abolis’ ideation-to-scale model, connecting microbial intelligence with its capabilities in strain engineering, enzyme modelling, fermentation, bioprocess development and scale-up. This allows partners to assess biological potential and industrial feasibility within the same development programme.

 

MINE supports applications across pharma and healthcare, cosmetics and personal care, food, nutrition and agriculture, including the development of ingredients, biotics, fermentation-derived products and bio-based alternatives.

 

Sylvia Julien, General Manager, MINE Business Unit, said: “The challenge in microbial biotechnologies lies in the difficulty of integrating the various pieces of information and, therefore, to know which signals matter and which hypotheses deserve further testing for product development. MINE gives teams a clearer way to navigate that complexity, helping them focus experimental work on the questions most likely to move a programme forward.”

 

The launch builds on Abolis’ wider focus on making microbial biotechnology more industrially actionable. Founded in 2014, the company combines expertise in industrial biotechnology, microbiology, microbial fermentation, metabolism, robotics and IP strategy to help partners translate biological research into validated, industrially relevant development routes.

 

Cyrille Pauthenier, Co-founder & CEO, Abolis, said: “MINE software release marks the point at which more than a decade of microbial-biotechnology, data and industrial experience of Abolis becomes a platform to boost partners’ research and our own research. 

 

"It strengthens Abolis’ ability to support decisions before, during and beyond experimentation, connecting biological evidence with the realities of validation, process development and scale-up. For our partners, that means a clearer route from microbial potential to an industrially relevant programme.”